CAS 2647949-48-0

Formula: C27H21F2N5O

InChI: InChI=1S/C27H21F2N5O/c1-17-6-4-11-25(32-17)27-21(18-12-13-30-24-10-3-2-7-19(18)24)15-34(33-27)16-26(35)31-14-20-22(28)8-5-9-23(20)29/h2-13,15H,14,16H2,1H3,(H,31,35)

InChI key: QGXRIRYULXOGDQ-UHFFFAOYSA-N

SMILES: CC1=NC(=CC=C1)C2=NN(C=C2C3=CC=NC4=CC=CC=C34)CC(=O)NCC5=C(C=CC=C5F)F

N-(2,6-Difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamide

CAS: 2647949-48-0

N-(2,6-Difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamide

Formula: C₂₇H₂₁F₂N₅O

Purezza: 98%

Peso molecolare: 469.49

Ref: 54-PC1046735

N-(2,6-Difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamide

CAS: 2647949-48-0

Purezza: 98%

Ref: IN-DA0H18X2

Ontunisertib

CAS: 2647949-48-0

Ontunisertib is a selective, orally available, gastrointestinal-restricted small-molecule inhibitor of TGFβ receptor I (ALK5/TGFβR1) that blocks the pro-fibrotic TGF-β/ALK5 signaling pathway, with a cellular ALK5 inhibition IC₅₀ ≤100 nM. By limiting systemic exposure and increasing local gastrointestinal drug exposure, Ontunisertib is primarily used for research on fibrostenotic Crohn's disease and intestinal fibrosis-related studies. Ontunisertib can also be used to study the mechanisms of fibrosis and inflammatory regulation mediated by TGF-β/ALK5 signaling.

Formula: C₂₇H₂₁F₂N₅O

Purezza: 99.38%

Peso molecolare: 469.485

Ref: TM-T205210